The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CD55 Antibody Market Research Report 2025
Synopsis
CD55 (decay-accelerating factor, DAF) is a GPI-anchored membrane glycoprotein that protects autologous cells from classical and alternative pathway of complement cascade.
Global CD55 Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD55 Antibody market research.
Key companies engaged in the CD55 Antibody industry include Merck, Thermo Fisher Scientific, Proteintech Group, Aviva Systems Biology, LifeSpan BioSciences, RayBiotech, Leading Biology, ProSci and Bethyl Laboratories, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of CD55 Antibody were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole CD55 Antibody market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CD55 Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Thermo Fisher Scientific
Proteintech Group
Aviva Systems Biology
LifeSpan BioSciences
RayBiotech
Leading Biology
ProSci
Bethyl Laboratories
OriGene Technologies
Novus Biologicals
Cell Signaling Technology
Abcam
GeneTex
United States Biological
St John's Laboratory
Creative Diagnostics
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CD55 Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
CD55 (decay-accelerating factor, DAF) is a GPI-anchored membrane glycoprotein that protects autologous cells from classical and alternative pathway of complement cascade.
Global CD55 Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD55 Antibody market research.
Key companies engaged in the CD55 Antibody industry include Merck, Thermo Fisher Scientific, Proteintech Group, Aviva Systems Biology, LifeSpan BioSciences, RayBiotech, Leading Biology, ProSci and Bethyl Laboratories, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of CD55 Antibody were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole CD55 Antibody market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CD55 Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Thermo Fisher Scientific
Proteintech Group
Aviva Systems Biology
LifeSpan BioSciences
RayBiotech
Leading Biology
ProSci
Bethyl Laboratories
OriGene Technologies
Novus Biologicals
Cell Signaling Technology
Abcam
GeneTex
United States Biological
St John's Laboratory
Creative Diagnostics
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CD55 Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD55 Antibody Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal
1.2.3 Polyclonal
1.3 Market by Application
1.3.1 Global CD55 Antibody Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Immunochemistry (IHC)
1.3.3 Immunofluorescence (IF)
1.3.4 Immunoprecipitation (IP)
1.3.5 Western Blot (WB)
1.3.6 ELISA
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CD55 Antibody Market Perspective (2018-2029)
2.2 CD55 Antibody Growth Trends by Region
2.2.1 Global CD55 Antibody Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CD55 Antibody Historic Market Size by Region (2018-2023)
2.2.3 CD55 Antibody Forecasted Market Size by Region (2024-2029)
2.3 CD55 Antibody Market Dynamics
2.3.1 CD55 Antibody Industry Trends
2.3.2 CD55 Antibody Market Drivers
2.3.3 CD55 Antibody Market Challenges
2.3.4 CD55 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CD55 Antibody Players by Revenue
3.1.1 Global Top CD55 Antibody Players by Revenue (2018-2023)
3.1.2 Global CD55 Antibody Revenue Market Share by Players (2018-2023)
3.2 Global CD55 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CD55 Antibody Revenue
3.4 Global CD55 Antibody Market Concentration Ratio
3.4.1 Global CD55 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD55 Antibody Revenue in 2022
3.5 CD55 Antibody Key Players Head office and Area Served
3.6 Key Players CD55 Antibody Product Solution and Service
3.7 Date of Enter into CD55 Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CD55 Antibody Breakdown Data by Type
4.1 Global CD55 Antibody Historic Market Size by Type (2018-2023)
4.2 Global CD55 Antibody Forecasted Market Size by Type (2024-2029)
5 CD55 Antibody Breakdown Data by Application
5.1 Global CD55 Antibody Historic Market Size by Application (2018-2023)
5.2 Global CD55 Antibody Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CD55 Antibody Market Size (2018-2029)
6.2 North America CD55 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CD55 Antibody Market Size by Country (2018-2023)
6.4 North America CD55 Antibody Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CD55 Antibody Market Size (2018-2029)
7.2 Europe CD55 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CD55 Antibody Market Size by Country (2018-2023)
7.4 Europe CD55 Antibody Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CD55 Antibody Market Size (2018-2029)
8.2 Asia-Pacific CD55 Antibody Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CD55 Antibody Market Size by Region (2018-2023)
8.4 Asia-Pacific CD55 Antibody Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CD55 Antibody Market Size (2018-2029)
9.2 Latin America CD55 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CD55 Antibody Market Size by Country (2018-2023)
9.4 Latin America CD55 Antibody Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CD55 Antibody Market Size (2018-2029)
10.2 Middle East & Africa CD55 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CD55 Antibody Market Size by Country (2018-2023)
10.4 Middle East & Africa CD55 Antibody Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck CD55 Antibody Introduction
11.1.4 Merck Revenue in CD55 Antibody Business (2018-2023)
11.1.5 Merck Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Detail
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific CD55 Antibody Introduction
11.2.4 Thermo Fisher Scientific Revenue in CD55 Antibody Business (2018-2023)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 Proteintech Group
11.3.1 Proteintech Group Company Detail
11.3.2 Proteintech Group Business Overview
11.3.3 Proteintech Group CD55 Antibody Introduction
11.3.4 Proteintech Group Revenue in CD55 Antibody Business (2018-2023)
11.3.5 Proteintech Group Recent Development
11.4 Aviva Systems Biology
11.4.1 Aviva Systems Biology Company Detail
11.4.2 Aviva Systems Biology Business Overview
11.4.3 Aviva Systems Biology CD55 Antibody Introduction
11.4.4 Aviva Systems Biology Revenue in CD55 Antibody Business (2018-2023)
11.4.5 Aviva Systems Biology Recent Development
11.5 LifeSpan BioSciences
11.5.1 LifeSpan BioSciences Company Detail
11.5.2 LifeSpan BioSciences Business Overview
11.5.3 LifeSpan BioSciences CD55 Antibody Introduction
11.5.4 LifeSpan BioSciences Revenue in CD55 Antibody Business (2018-2023)
11.5.5 LifeSpan BioSciences Recent Development
11.6 RayBiotech
11.6.1 RayBiotech Company Detail
11.6.2 RayBiotech Business Overview
11.6.3 RayBiotech CD55 Antibody Introduction
11.6.4 RayBiotech Revenue in CD55 Antibody Business (2018-2023)
11.6.5 RayBiotech Recent Development
11.7 Leading Biology
11.7.1 Leading Biology Company Detail
11.7.2 Leading Biology Business Overview
11.7.3 Leading Biology CD55 Antibody Introduction
11.7.4 Leading Biology Revenue in CD55 Antibody Business (2018-2023)
11.7.5 Leading Biology Recent Development
11.8 ProSci
11.8.1 ProSci Company Detail
11.8.2 ProSci Business Overview
11.8.3 ProSci CD55 Antibody Introduction
11.8.4 ProSci Revenue in CD55 Antibody Business (2018-2023)
11.8.5 ProSci Recent Development
11.9 Bethyl Laboratories
11.9.1 Bethyl Laboratories Company Detail
11.9.2 Bethyl Laboratories Business Overview
11.9.3 Bethyl Laboratories CD55 Antibody Introduction
11.9.4 Bethyl Laboratories Revenue in CD55 Antibody Business (2018-2023)
11.9.5 Bethyl Laboratories Recent Development
11.10 OriGene Technologies
11.10.1 OriGene Technologies Company Detail
11.10.2 OriGene Technologies Business Overview
11.10.3 OriGene Technologies CD55 Antibody Introduction
11.10.4 OriGene Technologies Revenue in CD55 Antibody Business (2018-2023)
11.10.5 OriGene Technologies Recent Development
11.11 Novus Biologicals
11.11.1 Novus Biologicals Company Detail
11.11.2 Novus Biologicals Business Overview
11.11.3 Novus Biologicals CD55 Antibody Introduction
11.11.4 Novus Biologicals Revenue in CD55 Antibody Business (2018-2023)
11.11.5 Novus Biologicals Recent Development
11.12 Cell Signaling Technology
11.12.1 Cell Signaling Technology Company Detail
11.12.2 Cell Signaling Technology Business Overview
11.12.3 Cell Signaling Technology CD55 Antibody Introduction
11.12.4 Cell Signaling Technology Revenue in CD55 Antibody Business (2018-2023)
11.12.5 Cell Signaling Technology Recent Development
11.13 Abcam
11.13.1 Abcam Company Detail
11.13.2 Abcam Business Overview
11.13.3 Abcam CD55 Antibody Introduction
11.13.4 Abcam Revenue in CD55 Antibody Business (2018-2023)
11.13.5 Abcam Recent Development
11.14 GeneTex
11.14.1 GeneTex Company Detail
11.14.2 GeneTex Business Overview
11.14.3 GeneTex CD55 Antibody Introduction
11.14.4 GeneTex Revenue in CD55 Antibody Business (2018-2023)
11.14.5 GeneTex Recent Development
11.15 United States Biological
11.15.1 United States Biological Company Detail
11.15.2 United States Biological Business Overview
11.15.3 United States Biological CD55 Antibody Introduction
11.15.4 United States Biological Revenue in CD55 Antibody Business (2018-2023)
11.15.5 United States Biological Recent Development
11.16 St John's Laboratory
11.16.1 St John's Laboratory Company Detail
11.16.2 St John's Laboratory Business Overview
11.16.3 St John's Laboratory CD55 Antibody Introduction
11.16.4 St John's Laboratory Revenue in CD55 Antibody Business (2018-2023)
11.16.5 St John's Laboratory Recent Development
11.17 Creative Diagnostics
11.17.1 Creative Diagnostics Company Detail
11.17.2 Creative Diagnostics Business Overview
11.17.3 Creative Diagnostics CD55 Antibody Introduction
11.17.4 Creative Diagnostics Revenue in CD55 Antibody Business (2018-2023)
11.17.5 Creative Diagnostics Recent Development
11.18 Biobyt
11.18.1 Biobyt Company Detail
11.18.2 Biobyt Business Overview
11.18.3 Biobyt CD55 Antibody Introduction
11.18.4 Biobyt Revenue in CD55 Antibody Business (2018-2023)
11.18.5 Biobyt Recent Development
11.19 Jingjie PTM BioLab
11.19.1 Jingjie PTM BioLab Company Detail
11.19.2 Jingjie PTM BioLab Business Overview
11.19.3 Jingjie PTM BioLab CD55 Antibody Introduction
11.19.4 Jingjie PTM BioLab Revenue in CD55 Antibody Business (2018-2023)
11.19.5 Jingjie PTM BioLab Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
